Ron H J Mathijssen
Overview
Explore the profile of Ron H J Mathijssen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
330
Citations
5016
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Guchelaar N, de Neijs M, Noordman B, Graaf H, van Hellemond I, van der Sluis P, et al.
EClinicalMedicine
. 2025 Mar;
81:103109.
PMID: 40026831
Background: The peritoneum is a common metastatic site in gastric cancer. The prognosis of synchronous peritoneal metastases compared to other metastatic sites in gastric cancer remains understudied. This study aims...
2.
Guchelaar N, Mathijssen R, de Boer M, van Bekkum M, Heijns J, Vriens B, et al.
EClinicalMedicine
. 2025 Feb;
80:103065.
PMID: 40017682
Background: Effective later-line chemotherapy treatment options are scarce for patients with metastatic breast cancer (MBC). Trifluridine-tipiracil has shown survival benefit in heavily pre-treated patients with metastatic colorectal and in gastric...
3.
Zietse M, Kooijman T, Malmberg R, Spierings L, Jager A, Mathijssen R, et al.
JCO Oncol Pract
. 2025 Feb;
:OP2400804.
PMID: 39983075
Purpose: The development of subcutaneous (SC) formulations for monoclonal antibodies (mAbs), as an alternative to conventional intravenous (IV) infusion, represents a shift in health care delivery. The relative environmental impact...
4.
Agema B, Koch B, Mathijssen R, Koolen S
Drugs
. 2025 Feb;
PMID: 39939511
One dose does not fit all, especially in oncolytic drugs, where side effects and therapy failures highlight the need for personalized dosing approaches. In recent years, the quest to apply...
5.
Buijs S, Jongbloed E, van Bergen L, Ramakers C, Koolen S, Mathijssen R, et al.
Br J Cancer
. 2025 Feb;
PMID: 39930149
Introduction: CDK4/6 inhibitors (CDK4/6i) improve progression-free survival in patients with advanced oestrogen-receptor-positive breast cancer. However, all CDK4/6i may increase creatinine levels, which can indicate kidney injury. In vitro research has...
6.
Malmberg R, Agema B, Hofman M, Oosterveld S, Bins S, Dumoulin D, et al.
Cancer Commun (Lond)
. 2025 Jan;
PMID: 39817458
No abstract available.
7.
van Nijnatten R, Buijs S, Agema B, Fischer R, Moghaddam-Helmantel I, Contant C, et al.
Breast
. 2025 Jan;
79:103880.
PMID: 39813819
Tamoxifen is an estrogen-receptor (ER) antagonist, used as adjuvant treatment of ER-positive breast cancer. It is converted by CYP2D6 into endoxifen, its most active metabolite. Patients with endoxifen plasma concentrations...
8.
Beyoglu D, Hamberg P, IJzerman N, Mathijssen R, Idle J
Biomed Pharmacother
. 2024 Dec;
182():117773.
PMID: 39693904
Ifosfamide causes neurotoxicity, including sometimes fatal encephalopathy, in a small number of patients. Why and how this occurs is not fully understood. It is generally believed that N-dechloroethylation of ifosfamide...
9.
Sikkema B, Baart S, Paats M, Smit E, Schols A, Mathijssen R, et al.
J Clin Oncol
. 2024 Dec;
43(6):641-650.
PMID: 39661917
Purpose: Weight gain is a known adverse event (AE) of alectinib. This study evaluates the progression of actual weight gain over time and explores its association with baseline characteristics. Methods:...
10.
Heersche N, Lanser D, Muntinghe-Wagenaar M, Mohmaed Ali M, Ulas E, Trooster T, et al.
J Thorac Oncol
. 2024 Dec;
PMID: 39617342
Introduction: Alectinib, a small-molecule kinase inhibitor, is used as first-line treatment for ALK-positive (ALK+) NSCLC. Albeit generally well-tolerated, a considerable subset of patients requires dose adjustments due to drug-related toxicity....